Other languages CURE BIOT OTC Markets

Equities

CUBT

US23128N2071

Market Closed - OTC Markets Other stock markets 15:59:39 2024-06-11 EDT			5-day change	1st Jan Change
0.0155 ^USD	-10.78%		-18.29%	-27.11%

05-06	Curative Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $7.999998 million.	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Curative Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	05-06
Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $7.999998 million.	11-25
Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $7.999998 million.	23-09-07
Curative Biotechnology, Inc. Announces Establishment of Japanese Subsidiary for Licensing Transactions and Asset Acquisitions	23-06-07
Curative Biotechnology, Inc. Announces Completion of IND Enabling Reformulated Metformin HCL Eye Drop Study	23-01-05
Curative Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-16
Curative Biotechnology, Inc. has filed an IPO in the amount of $7.999998 million.	22-11-07
Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $8 million.	22-10-31
Curative Biotechnology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-09-01
Curative Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-06-29
Curative Biotechnology Inc. Adds Biotech Veteran Lawrence S. Zaslow to Board of Directors	22-06-16
Curative Biotechnology, Inc. Appoints Cary Sucoff to Board of Directors	22-05-12
Curative Biotechnology, Inc. has filed an IPO.	22-04-15
Curative Biotechnology, Inc. Auditor Raises 'Going Concern' Doubt	22-04-14
Curative Biotechnology Announces Cooperative Research and Development Agreement with the National Eye Institute	22-03-21

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer